VE-821

Catalog No. A11605

VE-821是一种有效且选择性的蛋白激酶ATR抑制剂。
  • Mitsuru Sasaki-Honda, .et al. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4, Hum Mol Genet, 2018, Dec 1; 27(23): 4024-4035 PMID: 30107443
  • Kim J, .et al. Replication Stress Shapes a Protective Chromatin Environment across Fragile Genomic Regions, Mol Cell, 2018, Jan 4;69(1):36-47.e7 PMID: 29249653
  • Antonio Postigo, .et al. Cytoplasmic ATR Activation Promotes Vaccinia Virus Genome Replication, Cell Rep, 2017, May 2; 19(5): 1022-1032 PMID: 28467896
  • Nnennaya Kanu, .et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer, Genome Biol, 2016, 17: 185 PMID: 27634334
  • Carolyn Botting, .et al. H2AX phosphorylation and DNA damage kinase activity are dispensable for herpes simplex virus replication, Virol J, 2016, 13: 15 PMID: 26817608
Catalog Num A11605
M. Wt 468.4
Formula C18H16N4O3S
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1232410-49-9
Synonyms VE821
SMILES CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(C(=N2)C(=O)NC3=CC=CC=C3)N
VE-821是一种有效且选择性的蛋白激酶ATR抑制剂。
Targets
ATR (Cell-free assay)
13 nM(Ki)
In vitro (25°C) DMSO 65 mg/mL (176.43 mM)
Water Insoluble
Ethanol Insoluble
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 21.35 mL 106.75 mL 213.49 mL
0.5 mM 4.27 mL 21.35 mL 42.7 mL
1 mM 2.13 mL 10.67 mL 21.35 mL
5 mM 0.43 mL 2.13 mL 4.27 mL

*The above data is based on the productmolecular weight 468.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.